Studies on components of the plasma kallikrein system as a risk factor in diabetics undergoing cardiopulmonary bypass.
Components of the FX11-kallikrein systems were determined in blood samples from non diabetics and diabetics undergoing cardiopulmonary bypass (CPB). FX11 and prekallikrein levels fell in both groups with the largest falls in the diabetic group. Kallikrein inhibition was also lower in the diabetic group. Alpha-2-macroglobulin levels were lower in the diabetic group before operation and were markedly lower throughout CPB. Kallikrein like activities were also lower in the diabetic group. Beta FX11a inhibition values were higher in the diabetic group and fell in both groups during CPB. From the results obtained we concluded that the lower levels of FX11, prekallikrein, kallikrein inhibition and alpha-2-macroglobulin in the diabetic patients during CPB reflect enhanced activation of the FX11-plasma kallikrein systems. Blood loss in the diabetic group was higher than the for non diabetic group.
D015415:Biomarkers / Q000097:blood; D001026:Coronary Artery Bypass; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood*; D005174:Factor XII / Q000378:metabolism; D005260:Female; D006801:Humans; D007610:Kallikreins / Q000378:metabolism*; D008297:Male; D011288:Prekallikrein / Q000378:metabolism; D012307:Risk Factors; D000511:alpha-Macroglobulins / Q000378:metabolism
D015415:Biomarkers; D000511:alpha-Macroglobulins; D005174:Factor XII; D011288:Prekallikrein; D007610:Kallikreins